TY  - JOUR
TT  - Use of the new oral anticoagulants in clinical practice
AU  - Şahin, Şafak
AU  - Sarıkaya, Savaş
AU  - Taşlıyurt, Türker
PY  - 2013
DA  - June
JF  - Gaziosmanpaşa Üniversitesi Tıp Fakültesi Dergisi
JO  - Gaziosmanpaşa Tıp Dergisi
PB  - Tokat Gaziosmanpaşa Üniversitesi
WT  - DergiPark
SN  - 1309-3320
SP  - 59
EP  - 65
VL  - 5
IS  - 2
KW  - antikoagulan
KW  - dabigatran
KW  - rivaroxaban
KW  - warfarin
N2  - Until recently, warfarin had been the only treatment option for long-term oral anticoagulation of patients.However, warfarin therapy is challenging because of marked interindividual variability in dose and response, requiring frequent monitoring and dose titration.These limitations have prompted the clinical development of new oral anticoagulant.  Recently, New oral anticoagulant, dabigatran (direct thrombin inhibitor), and rivaroxaban (factor Xa inhibitors) have gained regulatory approval as alternative therapies to warfarin in Turkey.This review provides a concise remark for clinicians that evaluated the efficacy and safety of these drugs, their pharmacokinetic and pharmacodynamic properties, and a practical approach to their clinical use
UR  - https://dergipark.org.tr/tr/pub/gutfd/article/378787
L1  - https://dergipark.org.tr/tr/download/article-file/404372
ER  -